Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
World Respiratory Disorders Market 2009-2024
Management Report
Published: June 2009
Pages: 132
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 1499.00 Buy Now!
Research from: Visiongain
Sector: Indication Areas
Expanding patent populations and rising disease prevalence - World Respiratory Disorders Market 2009-2024 shows you where the opportunities lie in respiratory disorders
Respiratory disorder therapies form an important and competitive part of the pharmaceutical market worldwide. There are wide ranges of drugs and therapeutic needs, both acute and chronic. Revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. Our new pharma report - World Respiratory Disorders Market 2009-2024 - will give you the analytical information that you need to understand current trends and likely future events in this market area.
The years 2009 to 2015 will represent a period of high volatility in the respiratory therapeutics market, as important products face patent expiry and new drugs reach the market. What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market? Has the market reached saturation? Where do the opportunities really lie, and what are the main threats in this market? What are the crucial market drivers and restraints? This new report covers these and many other questions for respiratory therapies.
In particular, World Respiratory Disorders Market 2009-2024 discusses prospects for the following product types:
• Combination drugs (Advair/Seretide, Symbicort and Combivent)
• Corticosteroids (Pulmicort, Nasonex/Asmanex and Flovent/Flixotide)
• Leukotriene inhibitors (Singulair)
• Beta-2 agonists (Xopenex, Salamol and Ventolin)
• Antihistamines (Clarinex/Aerius, Allegra/Telfast and Zyrtec)
• Monoclonal antibodies (Synagis and Xolair)
• Other products (Spiriva, Prevnar, Tamiflu and influenza vaccines).
Comprehensive analysis of the respiratory market area
World Respiratory Disorders Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 70 tables and figures, 15 chapters and two interviews with experts. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.
Why you should buy World Respiratory Disorders Market 2009-2024
By buying this report you will receive the following benefits:
• You will receive a review of the existing market for respiratory disorder therapeutics
• You will receive overall revenue forecasts from 2009 to 2024, at market and sub-market level
• You will find out where leading products and companies are heading, with detailed sales forecasts from 2009 to 2024
• You will receive forecast revenues for leading geographical markets
• You will receive expert opinions from original research interviews
• You will receive well-informed analyses of market drivers and restraints, including SWOT analysis for the sector
• You will receive important pipeline information, seeing how present R&D is shaping the future in that market area.
Respiratory disorder drugs hold the potential for further high revenues. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.
You can order this report today
Do you want to know more about this important market? World Respiratory Disorders Market 2009-2024 will provide you with a greater understanding of that expanding market. You can stay ahead by ordering this report today.
Respiratory disorder therapies form an important and competitive part of the pharmaceutical market worldwide. There are wide ranges of drugs and therapeutic needs, both acute and chronic. Revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. Our new pharma report - World Respiratory Disorders Market 2009-2024 - will give you the analytical information that you need to understand current trends and likely future events in this market area.
The years 2009 to 2015 will represent a period of high volatility in the respiratory therapeutics market, as important products face patent expiry and new drugs reach the market. What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market? Has the market reached saturation? Where do the opportunities really lie, and what are the main threats in this market? What are the crucial market drivers and restraints? This new report covers these and many other questions for respiratory therapies.
In particular, World Respiratory Disorders Market 2009-2024 discusses prospects for the following product types:
• Combination drugs (Advair/Seretide, Symbicort and Combivent)
• Corticosteroids (Pulmicort, Nasonex/Asmanex and Flovent/Flixotide)
• Leukotriene inhibitors (Singulair)
• Beta-2 agonists (Xopenex, Salamol and Ventolin)
• Antihistamines (Clarinex/Aerius, Allegra/Telfast and Zyrtec)
• Monoclonal antibodies (Synagis and Xolair)
• Other products (Spiriva, Prevnar, Tamiflu and influenza vaccines).
Comprehensive analysis of the respiratory market area
World Respiratory Disorders Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 70 tables and figures, 15 chapters and two interviews with experts. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.
Why you should buy World Respiratory Disorders Market 2009-2024
By buying this report you will receive the following benefits:
• You will receive a review of the existing market for respiratory disorder therapeutics
• You will receive overall revenue forecasts from 2009 to 2024, at market and sub-market level
• You will find out where leading products and companies are heading, with detailed sales forecasts from 2009 to 2024
• You will receive forecast revenues for leading geographical markets
• You will receive expert opinions from original research interviews
• You will receive well-informed analyses of market drivers and restraints, including SWOT analysis for the sector
• You will receive important pipeline information, seeing how present R&D is shaping the future in that market area.
Respiratory disorder drugs hold the potential for further high revenues. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.
You can order this report today
Do you want to know more about this important market? World Respiratory Disorders Market 2009-2024 will provide you with a greater understanding of that expanding market. You can stay ahead by ordering this report today.
Companies Listed
American Academy of Allergy, Asthma & Immunology
American Thoracic Society
Apotex
Applied Molecular Evolution
Arrow Group Ltd
AstraZeneca
Biocryst
Boehringer Ingelheim
Breath Limited
British Lung Foundation
Centers for Disease Control and Prevention
Centers for Medicare and Medicaid Services
Chugai
Cipla
Daiichi Sankyo
Dr. Reddy's
Eli Lilly
European Medicines Agency
European Patent Office
Food and Drug Administration
Genentech
GeoPharm
GlaxoSmithKline
Hetero Drugs
Johnson & Johnson
Kyorin
MedImmune
Merck & Co
Mylan Inc
National Heart, Lung and Blood Institute
Novartis
Nycomed
Ono Pharmaceuticals
Orchid Pharmaceuticals
Perrigo
Pfizer
Ranbaxy
Roche
Sandoz
Sanofi-Aventis
Schering-Plough
Sepracor
Shanghai Pharmaceuticals
SkyePharma
Tanox Biosystems
Teva Pharmaceutical Industries
Theravance Inc
US Centers for Disease Control
World Health Organisation
Wyeth